This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Hepatoblastoma is a rare type of cancer that occurs in the liver. It usually affects children under the age of three and is the most common type of liver cancer in this age group. The exact cause of hepatoblastoma is unknown, but it is believed to be associated with genetic mutations. The main symptoms of hepatoblastoma include abdominal pain, jaundice, fever, weight loss, nausea, and vomiting. Other symptoms may include an enlarged liver, abdominal swelling, and a feeling of fullness in the abdomen. Diagnosis of hepatoblastoma is based on medical history, physical examination, imaging tests, and biopsy. Imaging tests such as computed tomography (CT) scans and magnetic resonance imaging (MRI) scans can help reveal the size and location of the tumor. A biopsy is necessary to determine if the tumor is cancerous or benign. Treatment of hepatoblastoma depends on the age of the patient, the type of tumor, and the stage. Surgery is the most common treatment option, and it is usually the first step in treating hepatoblastoma. The goal of surgery is to remove the tumor and any nearby lymph nodes. Radiation therapy or chemotherapy may also be used to help reduce the size of the tumor or to kill any remaining cancer cells. Hepatoblastoma is a rare form of cancer, but with early detection and treatment, many children can go on to live a long and healthy life. It is important to be aware of the signs and symptoms of hepatoblastoma and to talk to your doctor if you have any concerns.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States